Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) is a Healthcare stock tracked by StreetAlpha. CRL reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in CRL, 50% of them bullish and 50% bearish. In the past 30 days there were 7 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 13 | Morgan Stanley | Target raised | Buy | — |
| Sep 30 | UBS | Reinstated | Buy | — |
| Sep 28 | Jefferies | Maintained | Buy | — |
| Sep 25 | Deutsche Bank | Maintained | Buy | — |
| Sep 25 | TD Cowen | Target raised | Buy | — |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRL is in one of them and how their past CRL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRL in an article yet. Here's the latest on the wider market.
CRL Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Lori Chavez-DeRemerExecutive branch | Sell | $1K – $15K | Apr 28, 2025 | Sep 9, 2025 | 134 d |
| Jefferson ShreveR · IN | Sell | $15K – $50K | May 12, 2025 | Jun 22, 2025 | 41 d |
| Jefferson ShreveR · IN | Buy | $15K – $50K | May 8, 2025 | Jun 22, 2025 | 45 d |
| Rob BresnahanR · PA | Sell | $1K – $15K | May 15, 2025 | May 31, 2025 | 16 d |
| Ro KhannaD · CA | Sell | $1K – $15K | Apr 15, 2025 | May 12, 2025 | 27 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.